Campus Berlin-Buch

Last updated

Campus Berlin-Buch
Campus Berlin Buch 002.JPG
Entrance buildings during the Long Night of the Sciences, 2012
Established1990s (modern campus development)
Research typeScience, health and biotechnology cluster
Managing directors
Dr. Christina Quensel; Dr. Ulrich Scheller
Location Berlin, Germany
52°36′21″N13°29′17″E / 52.60583°N 13.48806°E / 52.60583; 13.48806
Affiliations Max Delbrück Center for Molecular Medicine, Leibniz Institute for Molecular Pharmacology, Charité – Universitätsmedizin Berlin

Campus Berlin-Buch is a science, health and biotechnology cluster in the Buch quarter of Berlin, Germany. It co-locates basic research institutes, clinical research units and numerous biotechnology companies and start-ups. Since reunification, the site has grown into one of Berlin's recognized "Zukunftsorte" (locations of the future) for innovation policy. [1]

Contents

The campus covers around 32 hectares and employs roughly 6,500 people in the health and biotechnology sector. [2] As of 2025, the managing directors are Dr. Christina Quensel and Dr. Ulrich Scheller. [3] [4]

History

The Buch area acquired a medical and scientific profile in the early 20th century with large hospital complexes. After 1945, during the German Democratic Republic period, institutes in Buch were reorganized under the Academy of Sciences. Following reunification, the site’s life-science profile was consolidated; in 1992 the Max Delbrück Center for Molecular Medicine (MDC) was founded, and the surrounding area developed a biotechnology focus. In the 2010s and 2020s the campus expanded with new research infrastructure and start-up facilities. Press coverage has described Berlin-Buch as one of Germany’s largest biomedicine-oriented locations. [1]

Focus and partners

Campus Berlin-Buch’s concept is to link “bench to bedside” translation between molecular and biomedical basic research, clinical environments and commercial application in biotechnology. Major stakeholders on or adjacent to the campus include the Max Delbrück Center for Molecular Medicine, the Leibniz Institute for Molecular Pharmacology (FMP), and clinical units affiliated with Charité. The campus also hosts dozens of SMEs and start-ups in diagnostics, devices and therapeutics. [1] [5]

Facilities and projects

BerlinBioCube (founders’ and incubation center)

In October 2023, a five-storey founders’ and incubation building called BerlinBioCube was inaugurated on the campus, adding about 8,000 m² of laboratory and office space. 14 young companies had secured space at opening, with roughly two thirds of the area pre-let. [6] The project is part of multi-million-euro investment plans for the BiotechPark. [7] [8]

Cryo-electron microscopy building

In September 2023, a new research building with a circa four-metre-tall cryo-electron microscope, reported to cost around five million euros, was opened for Berlin's structural biology community on the campus. [9]

Outreach and education: Gläsernes Labor

The campus hosts the Gläsernes Labor (Glass Laboratory), an out-of-school learning venue where secondary school students perform supervised experiments in molecular biology and related subjects. Newspaper reports highlight hands-on formats such as CRISPR/Cas sessions (“Gen-Schere”) offered to school classes. [10]

Policy context

The State of Berlin designates Campus Berlin-Buch as one of eleven official “Zukunftsorte” (future locations) for research and innovation policy. Government fact sheets describe the heart of the location as the 32-hectare campus with leading research institutes and one of Germany’s largest biotech parks, with around 6,500 people working in the local healthcare economy. [1] [2] [11]

Institutions and companies

Research / Healthcare institutions (selection)
Selected companies

See also

References

  1. 1 2 3 4 "Buch". Berlin.de (in German). Senate Department for Economics, Energy and Public Enterprises. 22 May 2023. Retrieved 3 October 2025.
  2. 1 2 "Zukunftsort Berlin-Buch (Kurzinfo)" (PDF). Berlin.de (in German). Retrieved 3 October 2025.
  3. Thomas Loy (11 September 2023). "Im Campus Buch forschen schon die Kita-Kinder". Der Tagesspiegel (in German). Retrieved 3 October 2025.
  4. "Campus Berlin-Buch GmbH". Business Location Center (State of Berlin). Retrieved 3 October 2025.
  5. 1 2 Christoph M. Kluge (18 August 2022). "Zu wenig Geld, zu viel Bürokratie: Berliner Pharma- und Biotech-Unternehmen in Sorge um den Standort". Der Tagesspiegel (in German). Retrieved 3 October 2025.
  6. Thomas Loy (11 October 2023). "Neues Zentrum für Medizin-Startups in Berlin-Buch". Der Tagesspiegel (in German). Retrieved 3 October 2025.
  7. Joachim Fahrun (30 September 2019). "Millionen-Investitionen im Biotech-Park Buch". Berliner Morgenpost (in German). Retrieved 3 October 2025.
  8. Thomas Schubert (1 September 2020). "400 Arbeitsplätze für Pankow: Ein "Bio Cube" am Campus Buch [400 jobs for Pankow: A "Bio Cube" at Campus Buch]". Berliner Morgenpost (in German). Retrieved 3 October 2025.
  9. Torsten Harmsen (14 September 2023). "Super-Mikroskop in Berlin-Buch: Blick in die kleinsten Puzzleteile des Lebens [Super microscope in Berlin-Buch: A look into the tiniest puzzle pieces of life]". Berliner Zeitung (in German). Retrieved 3 October 2025.
  10. Jana Ehrhardt-Joswig (13 April 2024). "Wenn Schüler mit der Gen-Schere experimentieren [When students experiment with gene scissors]". Berliner Morgenpost (in German). Retrieved 3 October 2025.
  11. "Berlin-Buch". Zukunftsorte Berlin (State of Berlin) (in German). Retrieved 3 October 2025.
  12. "Facts and figures". Max Delbrück Center. Retrieved 3 October 2025.
  13. "Arbeiten am FMP". Leibniz-FMP (in German). Retrieved 3 October 2025.
  14. "Campus Berlin Buch (CBB)". Charité (in German). Retrieved 3 October 2025.
  15. "Neuer Eckert & Ziegler-Chef Harald Hasselmann". Der Tagesspiegel (in German). 29 September 2023. Retrieved 3 October 2025.
  16. "Medizintechnik-Unternehmen Eckert & Ziegler baut Produktion in Pankow aus". Berliner Zeitung (in German). 13 October 2021. Retrieved 3 October 2025.
  17. "Contact". T-knife. Retrieved 3 October 2025.
  18. Pfohl, U.; Pflaume, A.; Regenbrecht, M.; Finkler, S.; Graf Adelmann, Q.; Reinhard, C.; Regenbrecht CRA; Wedeken, L. (2021). "Precision Oncology Beyond Genomics: The Future Is Here - Drug Response Prediction Using Patients' Tumor Avatars". Cancers. 10 (4). doi: 10.3390/cancers13092089 . PMC   8072767 . PMID   33920536. ASC Oncology GmbH, Robert-Rössle-Str. 10, 13125 Berlin
  19. "Contact". EPO Berlin-Buch. 14 March 2022. Retrieved 3 October 2025.
  20. "Radiopharma-focused Pentixapharm picks up Glycotope's discovery unit". FierceBiotech. 3 July 2024. Retrieved 3 October 2025.